#Lupus associated genetic variants contribute to organ damage #EULAR2019 https://t.co/644BudBQyp

Thomas Dorner tells us not to lose hope in lupus trials, and that they are just following what is called the Kuhn cycle! https://t.co/xeaaUwfwgp #EULAR2019

• The Kuhn Cycle - Thomas Kuhn's Brilliant Model of How Scientific Fields Progress

Genentech presenta nuevos datos sobre un nuevo tratamiento para el Lupus con afectación renal. Obinituzumab, Nueva esperanza para pacientes con nefritis lúpica! #EULAR2019 https://t.co/Jjl5zTBKGN

Dr Ross Wilkie won one of the Best Abstract Awards at the European Congress of Rheumatology #EULAR2019. His study identified targets for reducing premature death in older people with #osteoarthritis. Great research led by health professionals. #HPR https://t.co/RZ2salIn3M https://t.co/huAilBKUCG

• https://tinyurl.com/y4f4wwe4

Co-founder and Director of dotMD Dr Ronan Kavanagh explains what was involved in choosing speakers for this year’s conference https://t.co/FFiqxje4HF @DotMDConf @RonanTKavanagh

• http://ow.ly/Y4AW30oVeKN

Minimal Disease Activity in PsA is more challenging in women than in men. Unpublished data from the TICOPA trial presented by Dr. Laura Coates. #PsA #EULAR2019

What factors are linked with fatigue in women in the first year of #RA? One #EULAR2019 study found these 4: obesity, steroid use, seronegativity, and poor sleep https://t.co/40lyEXjE2U

New anti-CD20 Mab Obinutuzumab just delivered positive results in its phase 2 study in lupus nephritis. We need to know more! #EULAR2019 https://t.co/Bx9OdmEtpy

• Roche - Roche’s Gazyva (obinutuzumab) delivers positive topline results for pha…

Hydroxychloroquine: proposed risk factors for Retinopathy #EULAR2019 https://t.co/WkyNZ4GPVr

Mease: SEAM study MTX vs Etanercept in PsA. ETA effects > MTX with no additional benefit of combination. But some MTX benefit (note no PBO arm). Interesting separation between MTX<ETA for PASDAS (muli domain) but not DAPSA (joints only) #Eular2019 @RheumNow https://t.co/WSUlGE7NEf

#Gout patients tend not to tell doctors impact of gout on quality of life 👉🏼43% #mentalhealth 👉🏼27% impact on family 👉🏼26% relationship with partners ➡️🔟% lost job or retired due to gout by Meulemeester #EULAR2019 https://t.co/fyrAyvpaYO

Mease: Filgotinib (selective JAK1i) in active PsA ph2. Promising data. Interesting and informative way to present individual participant level data over time rather than just aggregate data - may be more useful for clinicians and patients to understand. #EULAR2019 @RheumNow https://t.co/B0pLODWGJ9

So, what are we left with? Some patients get another year free of remission - that’s good. TCZ is steroid-sparing - that’s good. Still questions about longer follow-up and sequelae, and a year’s therapy doesn’t cure everyone. It’s not a panacea for all GCA ills, but it’s a start! https://t.co/6AiIQLnLFN

Well it’s not all she wrote when flares come along, flares can be treated - some data on how to fix them, but beware the channeling bias https://t.co/o0rwYr1Ll7

McInnes: Machine-learning separates out 13 clusters of PsA in RCT population (i.e. already selected). Offers opportunities to reduce some of the massive heterogeneity in PsA to help inform biomarker studies and future precision medicine strategies. #Eular2019 @RheumNow https://t.co/h3Otp4Oq8U